nct_id: 'MK7902-014'
age: Adults
cancer_center_accrual_goal_upper: 0
data_table4: 'Interventional'
drug_list:
  drug:
    - drug_name: 'Pembrolizumab'
    - drug_name: 'Lenvatinib'
long_title: 'A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared With Standard of Care as First-line Intervention in Participants With Metastatic Esophageal Carcinoma'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: HKUMed
oncology_group_list:
  oncology_group:
  - group_name: Group 1
    is_primary: N
phase: '3'
principal_investigator: 'Professor Dora KWONG'
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program 1
protocol_id: 
protocol_no: ''
protocol_target_accrual: 0
protocol_type: ""
prior_treatment_requirements: 
  - 'Metastatic squamous cell carcinoma of the esophagus'
  - 'No GI obstruction, poor oral intake, difficulty in taking oral medication, or existing esophageal stent'
  - 'No known history of Hepatitis B or active Hepatitis C virus infection'
short_title: 'Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy'
site_list:
 site: []
sponsor_list:
 sponsor: []
staff_list:
 protocol_staff: []
status: open to accrual
summary: ''
treatment_list:
  step:
  - arm:
    - arm_code: Arm A
      arm_internal_id: 1111
      arm_description: 'Pembrolizumab + Lenvatinib + Chemotherapy'
      arm_suspended: N  
    - arm_code: Arm B
      arm_internal_id: 2222
      arm_description: 'Pembrolizumab + Chemotherapy'
      arm_suspended: N 
    step_code: '1'
    step_type: 'Registration'
    step_internal_id: 1111
    match:
        - and:
          - clinical:              
                oncotree_primary_diagnosis: 'Esophageal Squamous Cell Carcinoma'